José Trigo

6PUBLICATIONS
22CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 06, 2025
Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.

Sara Lonardi, Iwona Ługowska, Anne O'Donnell

|Jan 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.

Christos Chouaid, Lise Bosquet, Nicolas Girard

|Sep 24, 2022
Correction to: Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

José Trigo, Mónica García-Cosío, Almudena García-Castaño

|Jun 23, 2022
Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

José Trigo, Mónica García-Cosío, Almudena García-Castaño

|Nov 05, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis

|May 09, 2019
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

Emilie M J van Brummelen, Evgeny Levchenko, Manuel Dómine

Pageof 1

Frequent Collaborators

1 joint publications

Martin Gutierrez

1 joint publications

Victor Moreno

1 joint publications

Anthony J Olszanski

1 joint publications

Michael Ong